Onconetix, Inc. (ONCO): Nasdaq/NYSE listing notice — Onconetix receives Nasdaq deficiency notice for insufficient stockholders' equity; faces potential delisting

Onconetix, Inc.

Stockholders' equity was $1,404,476 for FY2023, below Nasdaq's $2.5M minimum requirement.
Company must submit a compliance plan to Nasdaq by June 24, 2024.
If plan accepted, Nasdaq may grant extension until November 4, 2024 to regain compliance.
Failure to regain compliance could result in delisting of ONCO common stock.
No immediate effect on listing; company can appeal any rejection decision.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Onconetix, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

equity for the fiscal year ended December 31, 2023 as reported in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2024 was $1,404,476, and as of the date of the Notice, the Company did not meet the alternatives to the Minimum Stockholders’ Equity Requirement of having either (i) a market value of listed

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-042369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.